The Pulse
The FDA is moving to close compounded GLP-1s for good, and a new study shows they never really stopped selling.
The FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, and a study published this month found compounded versions were still being sold for months after the shortage officially ended.
For any brand whose unit economics still lean on compounded supply, that revenue is now on a clock.
Migrate those patients to branded or authorized supply on your terms, before enforcement does it on theirs.
Branded GLP-1s are getting cheaper and easier to prescribe.
Noom, LifeMD, and Teladoc are now offering lower-cost single-vial Zepbound through their virtual programs, and Ro says the Wegovy pill is pulling in new patients, including more men.
The branded supply your compounded patients will move to is arriving at a lower price and through more doors than it was six months ago.
That makes the switch less scary than your patients think. Your job is to frame it that way before they Google it.
Digital health raised $7.4B in the first half, and buyers want retention, not reach.
Mental health led the market with $1.27B across 14 deals, and roughly 95% of digital health exits over the past year were acquisitions, not IPOs.
Strategic buyers are paying for proven lifecycle economics, not a big top-of-funnel number.
The brands getting bought are the ones that can show a patient stays and spends. That's a retention story, not an acquisition one.
The Deep Dive
The supply switch is the most under-managed churn moment in weight loss telehealth right now.
If compounded GLP-1s get pulled, millions of patients are being moved onto branded or authorized supply.
Different price. Different vial. Sometimes a different dosing schedule.
Most brands treat that as an operations problem. They send a notice that the medication is changing and a button to confirm.
That email is where you lose them.
Because a medication change reopens a decision the patient already closed. "Do I still want to do this?" lands back on the table, right when the price usually goes up.
And that reevaluation hits your best cohort hardest. The patients who've been on treatment longest are often the ones being switched first, and they carry the most LTV you have left to lose.
1. The switch is a decision point, not a logistics update.
A patient on autopilot doesn't think about canceling. A patient who just read "your treatment is changing" does.
You reopened the box. So the email that reopens it has to do the reselling too, not just the paperwork.
Remind them why they started. Show the progress they've already made. Then introduce the change as the next step, not a disruption.
The patients who churn here rarely leave angry. They just never click confirm, and the silence reads as gone.
2. Price is the objection, so handle it before they raise it.
Branded supply usually costs more than compounded did. If the first time a patient sees the new number is on the checkout screen, you've already lost the framing.
Name the new price in the switch email yourself. Put the lower-cost option right next to it in the same breath.
We've seen a quarterly-plan offer save a real slice of patients at exactly this moment, because the switch is when "too expensive" gets loudest.
One clear price, paired with one cheaper path, beats making a wavering patient hunt for either.
3. Route it through the provider, not the brand.
A medication change is a clinical event. It should sound like one.
A plain note from the patient's own provider, explaining why the switch is happening and that it's safe, outperforms a designed marketing email here every time.
Clinical authority is the one thing a nervous patient actually wants at a moment like this. Use it.
The takeaway: the compounding rules are handing you a forced conversation with every patient on that supply. Treat the switch email as a retention flow, not a shipping label, and you keep the patients your competitors will lose in the confusion.
Quick Takes
The capital is chasing retention, not reach.
Digital health raised $7.4B in the first half, and 95% of exits were acquisitions.
Nobody is buying a brand for its ad account. They're buying proven LTV: patients who stay, refill, and expand.
If you want to be acquirable, build the retention story now, because that's the number a buyer actually diligences.
The plateau is a separate churn moment from the switch, and it needs a different fix.
The supply switch is a forced event. The plateau is a quiet one.
Around month three to six, the scale stalls and the patient starts questioning the whole thing. A discount won't hold them there. A non-scale-wins reframe (energy, sleep, bloodwork, clothes fitting) will. Map both moments, because they don't respond to the same email.
One Thing to Try
Pull the email your brand sends when a patient's medication changes or their compounded script has to switch to branded.
Read it the way a patient would. If it's a logistics notice with a confirm button, that's a churn leak sitting in your flows right now.
Rewrite it as a provider-voice note: why the change is happening, the progress they've already made, the new price, and the lower-cost plan option in the same email.
Then add a reply path, so a hesitant patient can ask a question instead of quietly canceling.
Takes under an hour, and it protects revenue from a switch that's coming whether you prepare for it or not.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.